Logo Image
News
Media
Peer ExchangeCase-Based Psych PerspectivesClinical Case CollectiveClinical Forum InsightsInsightsPeers & PerspectivesPodcastsShortsSlideshowsVideos
Conferences
Conference CoverageConference Listing
Publication
Psychiatric Times
More
Job Board
CME/CE
Partners
Editorial
Resources
Between the LinesExpert PerspectivesClinical ConsultClinical ScalesInteractive ToolsLive EventsPartner PerspectivesQ&AQuizzesSeriesSpecial ReportsSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Publication
  • Job Board
  • CME/CE
  • Partners
  • Editorial
  • Resources
  • Subscribe
  • ADHD
  • Addiction & Substance Use
    • Behavioral Addictions
    • Opioid Use Disorder
    • Alcohol Use Disorder
    • Amphetamine Related Disorders
    • Substance Use Disorder
  • Alzheimer Disease & Dementia
  • Anxiety Disorders
    • Panic Disorder
  • Cannabis
  • Case Discussions
  • Comorbidity
  • Consultation-Liaison Psychiatry
    • COVID-19
  • Cultural Psychiatry
  • Drug Watch
  • Eating Disorders
  • Emergency Psychiatry
  • Ethics
  • Forensic Psychiatry
    • Munchausen Syndrome
    • Sexual Offenses
  • Integrative Psychiatry
  • Life Cycle Psychiatry
    • Postpartum Disorders
    • Geriatric Psychiatry
    • Child & Adolescent Psychiatry
  • Mental Health Awareness Month
  • Mood Disorders
    • Treatment-Resistant Depression
    • Major Depressive Disorder
    • Bipolar Disorder
  • Neuromodulation
  • Neuropsychiatry
    • Cognition
    • Dementia
    • Autism
  • Obsessive-Compulsive Disorders
  • PTSD, Trauma & Stress Disorders
    • Disaster Psychiatry
    • Trauma And Violence
    • Traumatic Stress Disorders
  • Personality Disorders
    • Compulsive Personality Disorder
    • Dependent Personality Disorder
    • Dissociative Identity Disorder
    • Histrionic Personality Disorder
    • Schizoid Personality Disorder
    • Antisocial Personality Disorder
    • Borderline Personality
  • Psychedelics & Cannabis
  • Psychiatry & Society
    • Diversity, Equity, Inclusion
    • Climate Change
    • Media & Psychiatry
  • Psychopharmacology
  • Psychosomatics
    • Delirium
    • Metabolic Disorders
    • Somatoform Disorder
  • Psychotherapy
    • Cognitive Behavioral Therapy
  • Schizophrenia/Psychosis
    • Paranoid Schizophrenia
    • Psychotic Affective Disorders
    • Schizoaffective
    • Schizophrenia Psychotic Features
    • Schizotypal Personality Disorder
    • Catatonic Schizophrenia
  • Sleep-Wake Disorders
    • Narcolepsy
    • Nocturnal Paroxysmal Dystonia
    • Sleep Deprivation
    • Sleep Wake Transition
    • Circadian Rhythm Sleep Disorders
  • Special Populations
    • Sports Psychiatry
    • Pervasive Developmental Disorder
    • LGBTQ+
    • Gender Issues
    • Military Mental Health
  • Suicide
  • Tardive Dyskinesia
  • Technology & Psychiatry
    • Digital Therapeutics
    • Artificial Intelligence
Spotlight -
Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|
Major Depressive Disorder
Advertisement

Bronwyn M. Graham, MPsychol (Clinical), PhD

Advertisement

Articles by Bronwyn M. Graham, MPsychol (Clinical), PhD

Mini Quiz: Hormone Levels and Trauma

ByBronwyn M. Graham, MPsychol (Clinical), PhD
January 9th 2019

A quiz on sex imbalance, anxiety disorders, and trauma.

sex imbalance in the prevalence of anxiety disorders

Sex Hormones and Gender Vulnerabilities to Anxiety Disorders

ByBronwyn M. Graham, MPsychol (Clinical), PhD
November 30th 2018

Clinicians can help raise awareness of the role of sex hormones in persistent anxiety by integrating 5 considerations into their practice.

Advertisement

Latest Updated Articles

  • sex imbalance in the prevalence of anxiety disorders
    Sex Hormones and Gender Vulnerabilities to Anxiety Disorders

    November 30th 2018

  • Mini Quiz: Hormone Levels and Trauma
    Mini Quiz: Hormone Levels and Trauma

    January 9th 2019



Advertisement
Advertisement

Trending on Psychiatric Times

1

Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia

2

FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia

3

Clozapine Remains Underused After REMS Elimination: A Conversation With Jose Rubio, MD, PhD

4

Phase 1 Clinical Studies Completed: NTX-253 for the Treatment of Schizophrenia

5

How a Learning Health Network Could Transform Bipolar Disorder Treatment: A Conversation With Andrew Nierenberg, MD

  • About
  • Advertise
  • Contact Us
  • Editorial
  • Terms and Conditions
  • Privacy Policy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us